Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Target Price at $45.71

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $45.7143.

Several equities research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a research report on Friday, August 14th.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP raised its holdings in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Zenas BioPharma by 4.5% during the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after acquiring an additional 554 shares during the last quarter. CWM LLC boosted its stake in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the last quarter. Two Sigma Investments LP increased its position in Zenas BioPharma by 3.9% during the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock worth $452,000 after purchasing an additional 765 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares in the last quarter.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $33.77 on Friday. The stock has a fifty day moving average price of $28.84 and a 200 day moving average price of $24.00. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The stock has a market cap of $2.20 billion, a PE ratio of -3.76 and a beta of -1.03. Zenas BioPharma has a 1 year low of $13.50 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. Sell-side analysts forecast that Zenas BioPharma will post -5.81 earnings per share for the current fiscal year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.